Epstein-Barr Virus

PCR Measurements Can Determine Treatment After Stem Cell Grafts

Published in Blood Weekly, September 6th, 2001

by Michael Greer, senior medical writer - Real-time measurement of Epstein-Barr virus (EBV) levels can help health care providers treat patients who develop EBV-related malignancies after stem cell transplantation, researchers in the Netherlands say.

"Epstein-Barr virus lymphoproliferative disease (EBV-LPD) following allogeneic stem cell transplantation (allo-SCT) has a poor prognosis," according to J.W.J. van Esser and colleagues at the University of Rotterdam Hospital.

However, the use of quantitative, real-time polymerase chain reaction (PCR) analysis to keep track of EPV loads allows doctors to rapidly determine the effectiveness of treatment...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-09-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry